Haisco Pharmaceutical Group Co Ltd, a China-based company focused on the research and development and marketing of therapeutic drugs, has agreed to make a $10 million equity investment in Pneuma Respiratory.  As part of the agreement, Haisco is to receive rights to distribute Pneuma Respiratory's pharmaceutical products in China. Haisco will be responsible for funding China regulatory filings.

Pneuma Respiratory, Inc. has developed the PNEUMAHALER™ Breath Actuated Digital Inhaler (BDI) to solve the problems of existing metered dose, dry- powder, and soft-mist inhalers to improve the efficacy of currently available airway medications. PNEUMAHALER BDI is the first pulmonary inhaler to merge advanced droplet ejector technology with digitally controlled breath-actuation, and package it in a lightweight, pocket-sized device.

Pneuma's go-to-market strategy is to marry the technology of its digital platform with off-patent drugs and create more efficacious treatments for asthma and COPD. Pneuma's strategy aims to de-risk its clinical and regulatory pathway and create value by rebranding off-patent therapeutic treatments within its patented PNEUMAHALER system to improve inhaled treatments for patients in the $39+ billion global asthma and COPD market.